Innate Pharma SA

IDDA

Company Profile

  • Business description

    Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

  • Contact

    117, Avenue de Luminy
    Marseille13009
    FRA

    T: +33 430303030

    E: [email protected]

    https://www.innate-pharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    179

Stocks News & Analysis

stocks

10 of the cheapest global companies with wide moats

These undervalued stocks of high-quality companies could be attractive investments today.
stocks

Bookworm: Buy and hold inspiration from an unlikely source

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks

3 ASX shares to avoid

These shares have surged in price in the last year but are significantly overvalued according to our analysts. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,082.1068.800.86%
CAC 408,053.0824.800.31%
DAX 4023,057.1770.350.31%
Dow JONES (US)41,488.19674.621.65%
FTSE 1008,643.4811.150.13%
HKSE24,145.57185.590.77%
NASDAQ17,754.09451.072.61%
Nikkei 22537,396.52343.420.93%
NZX 50 Index12,166.14100.11-0.82%
S&P 5005,638.94117.422.13%
S&P/ASX 2007,854.1064.400.83%
SSE Composite Index3,426.136.570.19%

Market Movers